ProShares Trust II has filed its quarterly report for the third quarter of 2026, detailing its financial performance and position. This update is significant as it provides insights into the company’s operations within the commodity contracts sector, which is characterized by its competitive nature and the need for transparency.
Founded in Delaware, ProShares Trust II operates primarily in the Commodity Contracts Brokers & Dealers industry, as indicated by its Standard Industrial Classification (SIC) code of 6221. The company is publicly listed and trades on major exchanges, including the NYSE and CBOE, with a variety of tickers such as AGQ, BOIL, and UVXY.
What the Filing Says
The filing, dated November 6, 2026, outlines the financial results for the period ending September 30, 2026. It emphasizes the company’s commitment to maintaining a robust financial position amidst fluctuating market conditions. Specific figures from the report were not disclosed in the filing, but it does mention that “the positions and counterparties herein are as of September 30, 2026,” indicating a snapshot of the company’s trading activities and financial commitments at that time.
Impact
This quarterly report could have implications for various stakeholders, including investors, analysts, and competitors. Investors will be particularly interested in the company’s performance metrics, which may influence their decisions regarding ProShares’ financial health and future prospects. Competitors in the commodity contracts space, such as Goldman Sachs and UBS, may also analyze this report to assess ProShares’ market positioning and strategies.
What's Next
The filing does not specify what happens next for ProShares Trust II. However, the company is expected to continue its regular reporting schedule, providing further updates on its financial performance and strategic initiatives in upcoming filings.
Read Next
Monroe Capital Income Plus Corp Releases Q3 Results
Great Southern Bancorp reports strong Q3 results
Tootsie Roll Industries reports Q3 results for 2026
Ellington Financial reports Q3 results amid market shifts
Anika Therapeutics reports Q3 results, emphasizes growth strategy
Mag Mile Capital Reports Q3 Results Amid Industry Challenges










